NCT07526545

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 800 (estimated)
• Sponsor: University of Michigan Rogel Cancer Center · Academic / Other
• Sex: Male
• Age: 50 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.

Conditions

• Prostate Carcinoma

Interventions

Type	Name	Description
PROCEDURE	Biopsy Procedure	Undergo biopsy
DEVICE	Diagnostic Procedure	Undergo MPS2 urine test
OTHER	Electronic Health Record Review	Ancillary studies
PROCEDURE	Magnetic Resonance Imaging	Undergo MRI

Timeline

• Start date: 2026-05-01
• Primary completion: 2029-11-01
• Completion: 2029-11-01
• First posted: 2026-04-13
• Last updated: 2026-04-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study